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ABSTRACT
Provision of reproductive services to individuals infected with HIV-1 is gaining popular ac-
ceptance and is generally endorsed by specialists in reproductive medicine. In the situation
in which the male is HIV positive and the female partner is not infected, a large body of ev-
idence has demonstrated that the use of assisted reproductive technology is effective for
achieving pregnancy, while eliminating the risk of viral transmission to the mother and fe-
tus. No reports have documented the well-being of the HIV-infected partners subsequent to
seeking fertility services. In the current report, we document the cases of five HIV-positive
men who died secondary to complications of HIV infection shortly after participating in the
assisted reproduction program for HIV-1–serodiscordant couples at Columbia University.
Three of these couples successfully achieved pregnancy and live birth, including one set of
triplets, and one case of posthumous conception; the fourth case resulted in the cryopreser-
vation of all embryos after the sudden death of the male before the time of embryo transfer;
the fifth couple failed to conceive. None of the deaths, which occurred within a few months
to 2 years from initial consultation, were related to infertility treatment. The demographic and
social statuses of these patients were not different from the general population of men seek-
ing assisted reproduction in our clinic. Regarding the HIV infection status of these cases, three
patients had a longer duration of infection compared to the general population of men in our
cohort, and one had a significantly lower CD4 cell count. All five men had stable HIV viral
loads, and were determined by their primary care providers to be clinically healthy at the
time of entry into the program for assisted reproduction. The untimely deaths of these pa-
tients underscores the importance of the thoughtful consideration of the complex issues in-
volved in family planning for these individuals, including advanced directives for the use of
cryopreserved gametes and embryos, and the social, emotional, and practical issues for the
children and surviving partners subsequent to the death of the HIV-positive parent.
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INTRODUCTION
THE AMERICAN COLLEGE OF OBSTETRICS & GY-NECOLOGY and the American Society for
Reproductive Medicine endorse the use of as-
sisted reproductive technologies for men,
women, and couples infected with HIV-1.1,2
These recommendations represent revisions of
previous opinions expressed by these agencies
and others,3–8 which were not generally in fa-
vor of the use of assisted reproduction for cou-
ples with HIV-1 serodiscordance. The changes
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in policies were at least partly influenced by the
dramatic improvement in survival of individ-
uals infected with HIV-1, largely because of the
development of highly active antiretroviral
therapy (HAART). With the reduction in AIDS
mortality,9 and the prolonged interval from in-
fection to death,10,11 it is reasonable to assume
that many HIV-1–seropositive patients of re-
productive age will consider having children.
In a survey of 1440 patients with HIV, 29% ex-
pressed desire for children,12 and many
serodiscordant couples reject the notion of us-
ing donor sperm for conception.13
HIV-1–serodiscordant couples now have the
opportunity to seek assisted reproduction for
infertility and minimization of viral transmis-
sion. The largest experience with assisted re-
production in couples with HIV-1 serodiscor-
dance in which the male is infected, comes from
the collective European database, where since
1989, more than 500 infants have been born af-
ter nearly 5000 cycles of assisted reproduction
in 7 countries without a single report of ma-
ternal or perinatal transmission.14 In the United
States, 18% of 182 fertility clinics that re-
sponded to a recent survey reported providing
some form of assisted reproduction to HIV-
1–infected couples,15 however, the extent of
services provided was not specified. In our
clinic, since 1997 we have performed over 250
cycles of in vitro fertilization with intracyto-
plasmic sperm injection (IVF-ICSI) on 130
serodiscordant couples of whom the male is
HIV-positive, yielding more than 100 babies
without a single maternal or perinatal infec-
tion. As the prevalence of HIV-1 continues to
grow in reproductive-aged patients,9 aware-
ness and utilization of such services is certain
to increase.
While the data favors optimism toward pro-
viding reproductive care to HIV-1–serodiscor-
dant couples, there have been few reports de-
tailing the lives of these individuals after their
participation in assisted reproduction pro-
grams. In our program, every effort is made to
ensure that HIV-1 testing is repeated 6 months
postpartum in mothers and infants in order to
verify that periconceptual and perinatal trans-
mission has not occurred. Care of the infected
parent, however, is the onus of the infectious
disease specialist, and there is generally a lack
of data in the reproductive medicine literature
concerning the short- and long-term outcomes
of treated patients. Death or incapacitation of a
seropositive patient after successful assisted
reproduction will undoubtedly have a pro-
found impact on the surviving partner and off-
spring.
In the current report, we describe five cases
in which the HIV-1–seropositive male partner
died within a short time after participating in
assisted reproduction. The deaths occurred
several months to 2 years after the initial con-
sult, and none of the fatalities were related to
infertility treatment. Three of the five couples
achieved live births including one set of
triplets, and one conception that was initiated
by frozen embryo transfer (FET) after the death
of the HIV-positive male partner. In the other
two cases, one woman cryopreserved all of her
embryos after the death of her husband, while
the other couple failed to achieve pregnancy
and had no cryopreserved embryos for later
transfer. While these patients represent a mi-
nority of our HIV-1–serodiscordant cohort,
their deaths emphasize the need to provide
thoughtful counseling to patients who are oth-
erwise favorable candidates for assisted repro-
duction.
MATERIALS AND METHODS
The protocol for offering IVF-ICSI to HIV-
1–serodiscordant couples in which the male is
infected was approved by the Institutional Re-
view Board (IRB) and the Ethics Committee of
Columbia University. We retrospectively re-
viewed the charts of 191 couples who 
presented for consultation for the IVF-ICSI 
program for HIV-serodiscordant couples at 
Columbia University between August 1997 and
December 2004. One-hundred thirty couples
met criteria for enrollment and participated in
the protocol. Serodiscordant couples in which
the female is HIV-positive are treated under a
similar IRB approved protocol but were not in-
cluded in the current data. Enrollment criteria
into our is described elsewhere.16 Briefly, HIV-
1–seropositive men were required to be in good
health, without active AIDS-defining illness,
verified by a letter of clearance from their in-
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fectious disease specialist. Treatment with an-
tiretrovirals was per discretion of the primary
care providers. Viral load (HIV-RNA-PCR) was
required to be less than 30,000 copies per mil-
liliter, and stable over 6 months. CD4 T-cell
counts also must have demonstrated stability
over the 6 months prior to treatment. Female
partners were required to demonstrate HIV-1
seronegativity using an enzyme immunoassay
(HIV-EIA) screen within 6 months of initiating
therapy. The long-term practice of safe sex with
condoms was ascertained at interview. A gen-
eral health and reproductive screening was
performed on couples prior to attempting as-
sisted reproduction, including serological test-
ing for hepatitis B and C. Hepatitis viremia
does not contraindicate IVF.17 Counseling by
specialists in Maternal Fetal Medicine and Psy-
chiatry or Social Services was encouraged and
readily available. Informed consent prior to
each cycle included an advanced directive re-
garding the fate of cryopreserved embryos and
semen in the event of the patient(s) death.
The processing of sperm was performed as
previously described.16 Handling of semen
samples from HIV-seropositive men was per-
formed in a separate class II biologic safety cab-
inet using strict universal precautions. The se-
men was centrifuged through a discontinuous
density gradient (Sage BioPharma, Bedminster,
NJ). The resulting pellet was transferred to a
clean conical tube and resuspended in modi-
fied human tubal fluid (HTF) (Irvine Scientific,
Santa Ana, CA) supplemented with 5% human
serum albumin (HSA) (Sage BioPharma). The
sperm were centrifuged for a maximum of 10
minutes at 300g, and the supernatant (wash
number 1) was removed. The pellet was resus-
pended in 3 mL of fresh modified HTF-HSA
and spun again for a maximum of 5 minutes.
The supernatant (wash number 2) was re-
moved, and the pellet was resuspended in a
small volume of modified HTF-HSA for swim-
up. The purified sperm were counted, and the
concentration was lowered, if necessary, to ap-
proximately 5 to 10  106 motile sperm per mil-
liliter (final sperm preparation). IVF-ICSI, the
process of individually fertilizing retrieved
oocytes by the injection of single spermatozoa,
was performed according to established pro-
tocol.18
Ongoing pregnancies were followed by Ma-
ternal Fetal Medicine in each trimester, and
HIV-RNA-PCR was performed on pregnant
women every 3 months during the pregnancy.
Infants and mothers were tested by either HIV-
RNA-PCR or HIV-DNA-PCR at birth and 3 and
6 months later. In nonpregnant patients, HIV-
EIA screens were performed 3 months after
embryo transfer. Patients were contacted an-
nually thereafter for additional follow-up, by
telephone or by mail when unreachable by
telephone.
RESULTS
Five HIV-1 seropositive male patients died
subsequent to participation in IVF-ICSI. The
characteristics of these patients are summa-
rized in Table 1.
The clinical course for the first couple was
previously described.19 After three unsuccess-
ful IVF cycles in Italy, the patient’s wife at age
40, presented to Columbia University for par-
ticipation in the program for HIV-1–serodis-
cordant couples. The husband, at age 36, sud-
denly died secondary to worsening pulmonary
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TABLE 1. CHARACTERISTICS OF THE HIV-SEROPOSITIVE MEN WHO DIED SUBSEQUENT TO IVF-ICSI
Duration of CD4 T-cell
Age HIV infection Viral load count Antiretroviral
Subject (years) Race (years) (copies per milliliter) (/mm3) Rx?
1 36 Caucasian 11 212 50 Yes
2 45 Caucasian 17 Undetectable 624 No
3 29 Caucasian 14 420 688 Yes
4 33 Caucasian 18 Undetectable 639 Yes
5 39 Caucasian 15 Undetectable 350 Yes
IVF-ICSI, in vitro fertilization with intracytoplasmic sperm injection.
hypertension shortly after the IVF-ICSI cycle.
The wife did not achieve pregnancy with the
fresh cycle, but returned 3 months later, seek-
ing the transfer of her cryopreserved embryos.
After consideration of the deceased’s directives
and the review by the Ethics Committee, an
FET was performed successfully. A healthy,
3000-gram male child was delivered by ce-
sarean section.
The second patient was 29 years old at ini-
tial consultation. He had a history of hemo-
philia and was coinfected with hepatitis C and
died secondary to complications of liver failure
approximately 1 month after the birth of his
children. The patient had a history of interferon
treatment and was not noted to be viremic
upon initiation of infertility treatment. The cou-
ple achieved pregnancy on the fourth cycle of
IVF, when three embryos implanted. Three
live-born infants were delivered via cesarean
section at 30 weeks secondary to severe
preeclampsia. All three were of very low birth
rate, with the smallest one suffering an intra-
ventricular hemorrhage. All children have
thrived and are developing normally at 1 year
of age.
The third patient presented at 33 years of age.
This patient also had a history of hemophilia
and hepatitis C with a history of interferon
treatment. The patient was not noted to be
viremic by the assessment of the patient’s pri-
mary care provider, nor did he suffer from any
other active comorbidities at the initiation of in-
fertility treatment. During the last few days of
his wife’s ovarian stimulation cycle, the patient
became acutely ill and suddenly died on the
day after oocyte aspiration. Postmortem exam-
ination determined aseptic meningitis as the
cause of death. All day 3 embryos were cryop-
reserved. One year later, the surviving spouse
renewed her agreement to continue storage of
her frozen embryos, and has yet to decide
whether or not she wishes to use them in the
future.
The fourth patient was 45 years old with a
history of azoospermia. The patient’s wife was
43 years old with normal ovarian parameters.
The couple attempted two cycles of IVF with
donor sperm but failed to become pregnant.
The patient died shortly thereafter secondary
to intracranial hemorrhage.
The fifth patient was 37 years old when first
presenting for care. He too was a hemophiliac
coinfected with HIV-1 and hepatitis C, treated
in the past with interferon. He and his wife
were successful in both attempts at IVF, and
delivered healthy children. Approximately 1
year after the birth of his second child, he suf-
fered a severe contusion of the leg, leading to
septicemia. Liver failure ensued and he died
while awaiting a liver transplant. The wife and
children remain well 2 years after his death.
No cases of HIV-1 seroconversion were de-
tected in any of the female partners or offspring
within the follow-up period (3 months post-
procedure for nonpregnant patients, and 6
months postpartum for patients who con-
ceived).
DISCUSSION
The deaths of these five patients in the short
term after undergoing assisted reproduction
underscores the tenuous situation of individu-
als with serious medical conditions who wish
to start families. These patients were generally
healthy and met criteria for entry into the pro-
gram for HIV-1–serodiscordant couples. Three
of the five patients had a significantly longer
duration of infection compared to the general
cohort of HIV-1–seropositive men in our pro-
gram (n  130, 8.6 years, 5.5; range, 1–20).
One patient had a CD4 count at the AIDS-defin-
ing level, but was stable and without a history
of opportunistic infections according to the pa-
tient’s infectious disease specialist, and was
given clearance for entering the program. For
all five patients, the HIV-RNA viral loads, a
sensitive prognosticator of morbidity,20 were
within the acceptable range for entry into the
clinical program and were comparable to the
general cohort of HIV positive men with de-
tectable viral loads (n  65, 3660 copies per mil-
liliter, 6338; range, 50–30,424), and were doc-
umented to be stable over the 6 months prior
to beginning therapy. All five of these patients
were Caucasian, as are most of the HIV-posi-
tive men in the cohort, and four of the five pa-
tients were on retroviral medications, also con-
sistent with the trend in the cohort (117/130 on
antiretroviral medications). The lack of obvious
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predictors for morbidity and mortality stresses
the potentially unpredictable course of HIV in-
fection even in clinically stable patients.
Offering assisted reproduction to HIV posi-
tive individuals remains controversial. The
risks of viral transmission from the semen of
HIV-positive men used for assisted reproduc-
tion warranted initial apprehension. In 1990, a
female in Virginia seroconverted after unsuc-
cessful insemination with her HIV-positive
husband’s sperm. While the events surround-
ing her infection remain controversial, the Cen-
ters for Disease Control cited this incident as a
reason not to support the use of insemination
of washed sperm as a means of reducing risk
of HIV transmission.21 In the 15 years since that
event, a large body of evidence has accumu-
lated favoring assisted reproductive tech-
niques, both sperm washing and IVF-ICSI, as
safe and useful for allowing conception in
serodiscordant couples. In the largest set of
data reported from Europe, not a single trans-
mission from an infected male to a female has
occurred when assisted reproduction, primar-
ily intrauterine insemination with washed
sperm, was used.14 Similarly, in our cohort,
which is significantly smaller than the Euro-
pean experience yet the largest in the United
States, using IVF-ICSI not a single infection has
occurred. With the infection rate for a single
unprotected act of intercourse between a HIV-
positive male and an uninfected female on the
order of 0.1%–0.2%,22,23 it is possible that the
current body of evidence is not powerful
enough to prove that assisted reproduction is
significantly safer than intercourse as a means
of reducing the risk of HIV transmission. How-
ever, the cumulative data strongly suggests
that assisted reproduction is effective and safe
for HIV-discordant couples and may provide
considerable risk reduction of viral transmis-
sion. The fetus is not at risk of infection as long
as the female remains virus free, because trans-
mission of HIV from a seronegative mother to
her neonate has never been documented.
Therefore, if assisted reproduction can be used
to eliminate periconceptual transmission from
a seropositive male to his seronegative partner,
perinatal infection appears implausible.
The impetus for considering childbearing for
HIV-positive individuals is the prolonged
longevity that many patients now enjoy as a re-
sult of advances in antiretroviral therapy. With
optimal management, the prospect for child
rearing appears realistic. Given the recent state-
ments that HIV-1 infection should not serve as
a sole contraindication to assisted reproduc-
tion,1,2 in addition to mounting opinion in the
field favoring fertility treatment for HIV-1–in-
fected patients,10,24,25 biases against providing
assisted reproduction to HIV-1–seropositive
patients appear to be gradually weakening. A
permissive attitude toward providing repro-
ductive care to HIV-1–seropositive patients rec-
ognizes the autonomy of infected individuals,
some of whom would assume risks to attempt
to conceive naturally in the absence of repro-
ductive assistance13; additionally, it protects
the welfare of the uninfected partner and the
offspring, who may be at a higher risk of in-
fection if assisted reproductive services were
not available. Compelling arguments have
been made comparing HIV-1 infection to other
chronic conditions that pose substantial threats
to the health of the mother and child, yet are
not categorical contraindications to assisted re-
production as HIV infection was classified in
the recent past.10 In light of the optimistic
trends in the management of HIV-1 and the fa-
vorable support for provision of fertility ser-
vices, physicians may feel obligated to provide
reproductive services to serodiscordant cou-
ples as they would to the general patient pop-
ulation. While we strongly advocate access 
to assisted reproductive services for HIV-
1–seropositive individuals and HIV-1–serodis-
cordant couples, as this report demonstrates,
these patients have unique risks, and several
important issues should be kept in mind when
providing fertility care.
Assuming both partners are making volun-
tary decisions to participate, of foremost im-
portance is the welfare of the offspring. Because
the risks of infection to the fetus or neonate in
the situation in which the father is seropositive
and the mother is seronegative appears to be
negligible, the pertinent issue then becomes the
social welfare of a child born to a HIV-1–in-
fected parent. The practical considerations are
obvious and no different than those that con-
front any family, albeit possibly more pressing
when a parent has a fatal disease. An acutely
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ill parent may not have the ability to simulta-
neously care for themselves and the child, thus
provisions must be made for when sickness en-
sues. In a large survey of HIV-1–seropositive
parents living with their children, 21% reported
being hospitalized during the previous 6
months, including 10% who had been hospi-
talized for 1 week or more.26 Estate planning,
and directives for guardianship are issues that
potential HIV-1–serodiscordant individuals
should address when making the decision for
child bearing. In a survey of a subset of our
HIV-1–serodiscordant population, who are not
representative of the socioeconomic demogra-
phy of the HIV-1–infected population in gen-
eral, most couples addressed the possibility of
raising a child alone in the event of a prema-
ture death of a spouse, but nearly 40% failed to
address the possibility of third-party parenting,
in the event of the demise of both parents.13
Any child of a parent with AIDS will certainly
be affected by their parent’s disease. The stigma
associated with HIV-1 can hinder access to sup-
port services that could potentially be of assis-
tance with coping.26 While such issues may be
uncomfortable topics of discussion, when a
couple presents for fertility consultation the
conversation should be forthright, as not all pa-
tients have considered the possibilities.
Explicit advanced directives are imperative
in reference to the use of cryopreserved gametes
and embryos, and their potential posthumous
use. Numerous ethical and legal issues sur-
round the topic of posthumous reproduction,
and legislature is variable with regards to the
reproductive rights of the surviving partner,
and survivorship entitlements of the resultant
offspring.27 Conception using the genetic mate-
rial of a deceased individual should only be en-
tertained according to the explicit advanced di-
rectives of that person.28 Because not all patients
who seek to start a family when they are alive
wish for the same in death, explicit directives
are of utmost importance to dictate the use of
gametes or embryos posthumously.29 If the de-
cision is duly made to proceed with posthu-
mous reproduction, again, the regards for the
welfare of the offspring are vital.
While the scope of this discussion and the
bulk of our experience is limited to HIV-posi-
tive men with seronegative female partners, the
treatment of HIV-positive women is also be-
coming increasingly frequent. Quoting the ben-
efits of HAART and the dramatically reduced
vertical transmission rates with current stan-
dards of care in pregnancy and labor, advo-
cates assert that HIV-positive females should
have full access to infertility services.30 When
serodiscordant couples are involved in a stable
relationship, it can be argued that the child will
have the benefit of being raised by at least one
healthy parent, thus it is less important which
parent is HIV positive. In the situation where
a HIV-positive woman is single and wishes to
conceive without a partner, the risk that a child
could be orphaned by AIDS is tenable, and
such a scenario deserves thoughtful delibera-
tion. To complicate matters further, because
HIV superinfection can occur between two pa-
tients with primary infections,31 it can be ar-
gued that assisted reproduction may be indi-
cated in couples in which both partners are
HIV-infected to reduce the risk of introduction
of resistant strains. The implications of HIV-
positive parenting are obviously compounded
when both parents are infected.
In conclusion, while we strongly advocate the
access to fertility care for HIV-infected individ-
uals, as the reported cases illustrate, serious is-
sues must be considered when counseling these
patients of the risks and benefits of assisted re-
production. While as the provider of fertility
treatment, the primary goal is to allow a safe con-
ception, the larger issues must not be ignored.
Children of HIV-infected persons can be consid-
ered part of the HIV-affected population,26 thus
the reproductive specialist potentially has a role
in impacting the disease burden. Frank discus-
sions and full disclosure are necessary to ensure
that HIV-positive individuals can make in-
formed, autonomous family planning decisions.
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